NASDAQ:ACCD Accolade (ACCD) Stock Price, News & Analysis → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free ACCD Stock Alerts $9.35 +0.14 (+1.52%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$9.06▼$9.6750-Day Range$8.25▼$13.1452-Week Range$6.33▼$17.00Volume637,496 shsAverage Volume718,426 shsMarket Capitalization$723.78 millionP/E RatioN/ADividend YieldN/APrice Target$15.53 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Accolade alerts: Email Address Accolade MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside66.1% Upside$15.53 Price TargetShort InterestBearish4.15% of Shares Sold ShortDividend StrengthN/ASustainability-0.89Upright™ Environmental ScoreNews Sentiment-0.24Based on 12 Articles This WeekInsider TradingSelling Shares$73,872 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.33) to ($1.20) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.81 out of 5 starsBusiness Services Sector66th out of 301 stocksBusiness Services, Not Elsewhere Classified Industry34th out of 86 stocks 3.4 Analyst's Opinion Consensus RatingAccolade has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 12 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageAccolade has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.15% of the outstanding shares of Accolade have been sold short.Short Interest Ratio / Days to CoverAccolade has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Accolade has recently increased by 15.47%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAccolade does not currently pay a dividend.Dividend GrowthAccolade does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAccolade has received a 76.67% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Private oncologist's appointments", "Private neurologist's appointments", "Private general practice doctor's diagnostic online appointments", "Private cardiologist's online appointments", and "Private gynaecologist's online appointments" products. See details.Environmental SustainabilityThe Environmental Impact score for Accolade is -0.89. Previous Next 1.0 News and Social Media Coverage News SentimentAccolade has a news sentiment score of -0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Business Services companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Accolade this week, compared to 3 articles on an average week. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Accolade insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $73,872.00 in company stock.Percentage Held by InsidersOnly 8.30% of the stock of Accolade is held by insiders.Percentage Held by Institutions84.99% of the stock of Accolade is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Accolade are expected to grow in the coming year, from ($1.33) to ($1.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Accolade is -5.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Accolade is -5.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAccolade has a P/B Ratio of 1.44. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad GoldenCrest MetalsExposed: How Big Banks Plan to Chain Your Wealth with Digital DollarsBig Banks have declared war on your wallet. But it's not too late to fight back. Discover how to protect your assets from their latest maneuver.Learn More Now About Accolade Stock (NASDAQ:ACCD)Accolade, Inc., together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians. It also provides medical opinion and decision support services; and technology and administrative services to the medical practice PCs providing virtual primary care services. The company serves employers who provide their employees and their employees' families a single place to turn for their health, healthcare, and benefits needs. Accolade, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.Read More ACCD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACCD Stock News HeadlinesApril 23, 2024 | finance.yahoo.comAccolade, Inc. (ACCD)April 23, 2024 | americanbankingnews.comAccolade (NASDAQ:ACCD) Price Target Cut to $13.00 by Analysts at Stifel NicolausApril 24, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 22, 2024 | benzinga.comAlphabet To Rally Around 14%? Here Are 10 Top Analyst Forecasts For MondayApril 21, 2024 | investing.comAccolade CEO Rajeev Singh sells $3.1k in stockApril 18, 2024 | morningstar.comAccolade Inc Ordinary SharesApril 18, 2024 | americanbankingnews.comAccolade (ACCD) Scheduled to Post Quarterly Earnings on ThursdayApril 14, 2024 | uk.investing.comAccolade CFO exercises options, sells shares for tax obligationsApril 24, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 5, 2024 | seekingalpha.comAccolade: Staying Bullish On Favorable DevelopmentsApril 3, 2024 | finance.yahoo.comAccolade to Announce Fiscal Fourth Quarter 2024 Financial ResultsApril 1, 2024 | finance.yahoo.comRecent uptick might appease Accolade, Inc. (NASDAQ:ACCD) institutional owners after losing 24% over the past yearMarch 20, 2024 | prnewswire.comAccolade Wins 2024 Artificial Intelligence Excellence AwardMarch 19, 2024 | businesswire.comNational Accolade Bestowed on Arkansas-Based Provider: ‘Best Rural High Speeds'March 19, 2024 | prnewswire.comAccolade Promotes Kelsi McDonald Harris to Chief People OfficerMarch 17, 2024 | finance.yahoo.comACCD Apr 2024 10.000 callMarch 16, 2024 | finance.yahoo.comACCD Apr 2024 12.500 callMarch 15, 2024 | barrons.comAccolade Inc.March 12, 2024 | proactiveinvestors.comChesapeake Bank receives AARP accolade for combatting financial exploitationFebruary 28, 2024 | globenewswire.comAccolade To Present at Upcoming Investor ConferencesFebruary 27, 2024 | prnewswire.comAccolade Welcomes Brightline to Trusted Partner EcosystemFebruary 26, 2024 | msn.comLeerink Partners Initiates Coverage of Accolade (ACCD) with Outperform RecommendationFebruary 26, 2024 | markets.businessinsider.comAccolade Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)February 23, 2024 | investorplace.comAlabama's Fertility Ruling Raises Challenges for Stocks of Fertility Benefits ProvidersFebruary 22, 2024 | benzinga.comAccolade Stock (NASDAQ:ACCD), Short Interest ReportFebruary 7, 2024 | ca.finance.yahoo.comPLTR Mar 2024 12.000 putFebruary 5, 2024 | finance.yahoo.comDoes Accolade (ACCD) Have the Potential to Rally 25.58% as Wall Street Analysts Expect?See More Headlines Receive ACCD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Accolade and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/27/2023Today4/24/2024Next Earnings (Confirmed)4/25/2024Fiscal Year End2/28/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorBusiness Services Industry Business services, not elsewhere classified Sub-IndustryN/A Current SymbolNASDAQ:ACCD CUSIPN/A CIK1481646 Webaccolade.com Phone206-926-8100FaxN/AEmployees2,370Year FoundedN/APrice Target and Rating Average Stock Price Target$15.53 High Stock Price Target$19.00 Low Stock Price Target$12.00 Potential Upside/Downside+66.1%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage16 Analysts Profitability EPS (Most Recent Fiscal Year)($1.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-459,650,000.00 Net Margins-31.59% Pretax Margin-31.48% Return on Equity-27.27% Return on Assets-14.36% Debt Debt-to-Equity Ratio0.48 Current Ratio2.35 Quick Ratio2.35 Sales & Book Value Annual Sales$363.14 million Price / Sales1.99 Cash FlowN/A Price / Cash FlowN/A Book Value$6.51 per share Price / Book1.44Miscellaneous Outstanding Shares77,410,000Free Float70,983,000Market Cap$723.78 million OptionableOptionable Beta2.08 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Rajeev Singh (Age 56)Chairman of the Board & CEO Comp: $778.5kMr. Robert Cavanaugh (Age 55)President Comp: $582.63kMr. Stephen H. Barnes CPA (Age 52)CFO & Treasurer Comp: $557.5kMs. Kristen BruzekSenior Vice President of OperationsMr. Colin McHugh (Age 45)Chief Accounting Officer Mr. Todd FriedmanSenior Vice President of Investor RelationsMr. Richard Eskew (Age 49)Executive VP, General Counsel, CCO & Secretary Ms. Kelsi McDonald HarrisChief People Officer & Senior Vice PresidentMr. Drew GarnerExecutive Vice President of EngineeringDr. Shantanu Nundy M.B.A.M.D., Executive VP of Care Delivery, Chief Health Officer & Member of the Medical Advisory BoardMore ExecutivesKey CompetitorsInternational Money ExpressNASDAQ:IMXIViadNYSE:VVIConduentNASDAQ:CNDTPaysafeNYSE:PSFELiquidity ServicesNASDAQ:LQDTView All CompetitorsInsiders & InstitutionsSumitomo Mitsui Trust Holdings Inc.Sold 104,934 shares on 4/19/2024Ownership: 2.193%Rajeev SinghSold 355 sharesTotal: $3,131.10 ($8.82/share)Stephen H BarnesSold 109 sharesTotal: $961.38 ($8.82/share)Robert N CavanaughSold 141 sharesTotal: $1,243.62 ($8.82/share)Allspring Global Investments Holdings LLCBought 8,258 shares on 4/18/2024Ownership: 0.011%View All Insider TransactionsView All Institutional Transactions ACCD Stock Analysis - Frequently Asked Questions Should I buy or sell Accolade stock right now? 16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Accolade in the last twelve months. There are currently 4 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ACCD shares. View ACCD analyst ratings or view top-rated stocks. What is Accolade's stock price target for 2024? 16 brokerages have issued 12-month target prices for Accolade's stock. Their ACCD share price targets range from $12.00 to $19.00. On average, they expect the company's stock price to reach $15.53 in the next twelve months. This suggests a possible upside of 66.1% from the stock's current price. View analysts price targets for ACCD or view top-rated stocks among Wall Street analysts. How have ACCD shares performed in 2024? Accolade's stock was trading at $12.01 on January 1st, 2024. Since then, ACCD shares have decreased by 22.1% and is now trading at $9.35. View the best growth stocks for 2024 here. When is Accolade's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024. View our ACCD earnings forecast. How can I listen to Accolade's earnings call? Accolade will be holding an earnings conference call on Thursday, April 25th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link. How were Accolade's earnings last quarter? Accolade, Inc. (NASDAQ:ACCD) posted its earnings results on Thursday, April, 27th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.01. The business earned $99.03 million during the quarter, compared to analyst estimates of $99.44 million. Accolade had a negative trailing twelve-month return on equity of 27.27% and a negative net margin of 31.59%. Accolade's quarterly revenue was up 5.6% compared to the same quarter last year. During the same period last year, the company earned ($0.59) EPS. What ETFs hold Accolade's stock? ETFs with the largest weight of Accolade (NASDAQ:ACCD) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), SPDR S&P Health Care Services ETF (XHS), Fidelity Digital Health ETF (FDHT) and First Trust Nasdaq Lux Digital Health Solutions ETF (EKG).iShares U.S. Healthcare Providers ETF (IHF). What is Rajeev Singh's approval rating as Accolade's CEO? 152 employees have rated Accolade Chief Executive Officer Rajeev Singh on Glassdoor.com. Rajeev Singh has an approval rating of 74% among the company's employees. What other stocks do shareholders of Accolade own? Based on aggregate information from My MarketBeat watchlists, some companies that other Accolade investors own include CVS Health (CVS), Johnson & Johnson (JNJ), RTX (RTX), Alibaba Group (BABA), Home Depot (HD), Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO) and Intel (INTC). When did Accolade IPO? Accolade (ACCD) raised $176 million in an IPO on Thursday, July 2nd 2020. The company issued 8,800,000 shares at $19.00-$21.00 per share. Goldman Sachs, Morgan Stanley and BofA Securities served as the underwriters for the IPO and Piper Sandler, Credit Suisse, William Blair, Baird and SVB Leerink were co-managers. Who are Accolade's major shareholders? Accolade's stock is owned by many different institutional and retail investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (2.19%), Los Angeles Capital Management LLC (0.07%) and Allspring Global Investments Holdings LLC (0.01%). Insiders that own company stock include Colin Mchugh, Michael W Hilton, Rajeev Singh, Richard Eskew, Robert N Cavanaugh and Stephen H Barnes. View institutional ownership trends. How do I buy shares of Accolade? Shares of ACCD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ACCD) was last updated on 4/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencySHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsThe #1 Crypto for 2024InvestorPlaceMan Who Predicted 2008: “This Will be Worse.”AltimetryBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Accolade, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
